Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 3.

Journal Article

Felip, E., Minotti, V., Soo, R., Wolf, J., Solomon, B., Tan, D. S. W., Ardizzoni, A., Lee, D. H., Sequist, L. V., Barlesi, F., Paz-Ares, L., Rodriguez-Abreu, D., Garcia Campelo, M. R., Sprauten, M., Djentuh, L. O'Sullivan, Belli, R., Glaser, S., Zou, M., Giovannini, M. and Yang, J. C-H. (2020). MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer. Ann. Oncol., 31. S. S829 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Felip, E., Van Meerbeeck, J., Wolf, J., Ardizzoni, A., Li, A., Srinivasan, S. and Popat, S. (2016). CheckMate 171: A multicenter phase 2 trial of nivolumab (nivo) in patients (pts) with stage IIIB/IV squamous cell (SQ) NSCLC who have received >= 1 prior systemic treatment. J. Thorac. Oncol., 11 (4). S. S141 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Popat, S., Ardizzoni, A., Ciuleanu, T., Cobo Dols, M., Laktionov, K., Szilasi, M., Califano, R., Carcereny Costa, E., Griffiths, R., Paz-Ares, L., Szczylik, C., Corral, J., Isla, D., Jassem, J., Appel, W., Van Meerbeeck, J., Wolf, J., Jiang, J., Molife, L. R. and Felip Font, E. (2017). Nivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged >= 70 years and with poor performance status. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

This list was generated on Thu Mar 28 16:09:01 2024 CET.